IMMUSOFT
Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft. The technology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. It was founded in 2009 and is headquartered in Seattle, Washington.
IMMUSOFT
Industry:
Biotechnology Life Science Therapeutics
Founded:
2009-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.immusoft.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
41.27 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-03-09 | Discovery Genomics | Discovery Genomics acquired by Immusoft | N/A |
Investors List
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Grant - Immusoft
Breakout Ventures
Breakout Ventures investment in Venture Round - Immusoft
Mesa Verde Venture Partners
Mesa Verde Venture Partners investment in Venture Round - Immusoft
National Institutes of Health
National Institutes of Health investment in Grant - Immusoft
Ikarian Capital
Ikarian Capital investment in Venture Round - Immusoft
Breakout Ventures
Breakout Ventures investment in Series B - Immusoft
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Immusoft
RBV Capital
RBV Capital investment in Series B - Immusoft
GRIDS Capital
GRIDS Capital investment in Series B - Immusoft
Mesa Verde Venture Partners
Mesa Verde Venture Partners investment in Series B - Immusoft
Official Site Inspections
http://www.immusoft.com
- Host name: ec2-34-238-11-122.compute-1.amazonaws.com
- IP address: 34.238.11.122
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Immusoft"
Immusoft - Crunchbase Company Profile & Funding
Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s …See details»
Immusoft - LinkedIn
Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells.See details»
Immusoft Company Profile - Office Locations, Competitors ... - Craft
Immusoft has 5 employees across 2 locations and $9.4 m in total funding,. See insights on Immusoft including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Immusoft Company Profile 2024: Valuation, Funding
Immusoft General Information Description. Developer of novel therapies designed for the treatment of rare diseases. The company develops autologous cell therapies based on its immune system programming technology that entails …See details»
Immusoft: Contact Details and Business Profile - RocketReach
Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is …See details»
Immusoft - The Org
Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells.See details»
Immusoft - Products, Competitors, Financials, Employees, …
About Immusoft. Immusoft is a cell therapy company specializing in the development of novel therapies for rare diseases. The company's main offering is a technology platform called …See details»
Immusoft | VentureRadar
Immusoft Corporation's (immusoft.com) mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP?). The technology modifies a …See details»
Immusoft - Contacts, Employees, Board Members, Advisors
Organization. Immusoft . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... About. Immusoft has 5 current employee profiles, …See details»
About - Immusoft
Rob Hayes Chief Scientific Officer . Dr. Robert Hayes is the Chief Scientific Officer at Immusoft, where he oversees Immusoft’s preclinical research and spearheads the near-term advancement of ISP-001 for the treatment of …See details»
Immusoft - Overview, News & Similar companies | ZoomInfo.com
Dec 14, 2023 Who is Immusoft. Immusoft Corporation's mission is to treat diseases using its technology platform called Immune System Programming. The technology modifies a patie …See details»
Immusoft - Funding, Financials, Valuation & Investors - Crunchbase
Immusoft is funded by 23 investors. California Institute for Regenerative Medicine and California Institute for Regenerative Medicine are the most recent investors. Immusoft has a post-money …See details»
Immusoft - Company Profile - Tracxn
Aug 17, 2021 Immusoft ranks 10th among 119 active competitors. 46 of its competitors are funded while 38 have exited. Overall, Immusoft and its competitors have raised over $4.27B in …See details»
Immusoft Announces FDA Clearance of IND Application for ISP …
Sep 1, 2022 Immusoft is a clinical stage cell therapy company focused on developing novel therapies for rare diseases using a sustained delivery of protein therapeutics from a patient’s …See details»
In a first, Immusoft gives engineered B cell in a clinical trial
Dec 15, 2023 Immusoft has administered an engineered B cell to a human for the first time, marking a milestone in its long-running quest to create a new type of medicine.. The West …See details»
Matthew Scholz - Immusoft
Matthew Scholz is Immusoft’s founder and served as the company’s Chief Executive Officer from 2009 through 2017. Immusoft’s inflection point as a company came when Matthew conceived …See details»
Immusoft Scores Deal Worth More than $900M With Takeda to …
Oct 14, 2021 Cell therapy biotech Immusoft will partner Takeda to develop new cell therapies to target rare inherited metabolic disorders with central nervous system (CNS) manifestations …See details»
Press Releases Archives - Immusoft
SEATTLE–(BUSINESS WIRE)– Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the …See details»
Immusoft Pipeline - Immusoft
© IMMUSOFT 2024 | 454 N 34th St., Seattle, WA 98103 | Directions | [email protected] | [email protected]See details»